(Q34070917)

30 July 2017

1 reference

title

Continuous dopamine-receptor stimulation in early Parkinson's disease (English)

1 reference

30 July 2017

0 references

1 reference

Olanow W

1

1 reference

30 July 2017

Schapira AH

series ordinal

2

1 reference

30 July 2017

Rascol O

series ordinal

3

1 reference

30 July 2017

publication date

1 October 2000

1 reference

30 July 2017

published in

Trends in Neurosciences

1 reference

30 July 2017

volume

23

1 reference

30 July 2017

issue

10 Suppl

1 reference

30 July 2017

page(s)

S117-26

1 reference

Parkinson's disease. First of two parts

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

The functional anatomy of basal ganglia disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Primate models of movement disorders of basal ganglia origin

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Opposite modulation of cortical N-methyl-D-aspartate receptor-mediated responses by low and high concentrations of dopamine.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

The metabolic topography of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Pathophysiology of the basal ganglia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Single-axon tracing study of neurons of the external segment of the globus pallidus in primate

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Dye coupling between rat striatal neurons recorded in vivo: compartmental organization and modulation by dopamine.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Posteroventral medial pallidotomy in advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Effects of apomorphine on globus pallidus neurons in parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Continuous and intermittent levodopa differentially affect basal ganglia function

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Dopamine receptors: from structure to behavior

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Pargyline Prevents MPTP-Induced Parkinsonism in Primates

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

Tolcapone and hepatotoxic effects. Tasmar Advisory Panel

1 reference

https://api.crossref.org/works/10.1016%2FS1471-1931%2800%2900030-6

7 January 2021

10.1016/S1471-1931(00)00030-6

Identifiers

DOI

1 reference

30 July 2017

1 reference